Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts
- PMID: 11196192
Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts
Abstract
Antiangiogenic therapy can enhance radiation-induced tumor growth inhibition. However, the effects of combined antiangiogenic and radiation therapy on long-term tumor control and normal tissue response have not been reported. We treated mice bearing two different human tumor xenografts with anti-vascular endothelial growth factor receptor-2 antibody (DC101) and five dose fractions of local radiation and followed them for at least 6 months. DC101 significantly decreased the dose of radiation necessary to control 50% of tumors locally. The decrease was 1.7- and 1.3-fold for the moderately radiosensitive small cell lung carcinoma 54A and the highly radioresistant glioblastoma multiforme U87, respectively. In contrast to tumors, no increase in skin radiation reaction by the antibody was detected. Surprisingly, 44% of mice bearing 54A tumor developed clear ascites after DC101 treatment at its highest dose; this was fatal to 20% of mice. This adverse effect was seen only in mice that received whole-body irradiation 1 day before tumor implantation. The encouraging results on two human tumor xenografts suggest that vascular endothelial growth factor receptor-2 blockade merits further investigation to assess its potential as an enhancer of radiation therapy in the clinic.
Similar articles
-
Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.Cancer Res. 2001 Sep 15;61(18):6624-8. Cancer Res. 2001. PMID: 11559524
-
Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.Cancer Res. 2002 Apr 1;62(7):2034-42. Cancer Res. 2002. PMID: 11929822
-
Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.Cancer Res. 2000 Oct 1;60(19):5565-70. Cancer Res. 2000. PMID: 11034104
-
Molecular modalities in the treatment of lung cancer.Oncology (Williston Park). 1999 Oct;13(10 Suppl 5):142-7. Oncology (Williston Park). 1999. PMID: 10550839 Review.
-
[The histological types and the effects of radiation on tumors].Gan No Rinsho. 1989 Oct;35(13):1499-505. Gan No Rinsho. 1989. PMID: 2685390 Review. Japanese.
Cited by
-
Radiotherapy in combination with vascular-targeted therapies.Radiol Oncol. 2010 Jun;44(2):67-78. doi: 10.2478/v10019-010-0025-9. Epub 2010 May 24. Radiol Oncol. 2010. PMID: 22933894 Free PMC article.
-
In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors.Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):7866-71. doi: 10.1073/pnas.122157899. Proc Natl Acad Sci U S A. 2002. PMID: 12060733 Free PMC article.
-
Normalization of the vasculature for treatment of cancer and other diseases.Physiol Rev. 2011 Jul;91(3):1071-121. doi: 10.1152/physrev.00038.2010. Physiol Rev. 2011. PMID: 21742796 Free PMC article. Review.
-
Evaluation of antiangiogenic effects of a new synthetic candidate drug KR-31831 on xenografted ovarian carcinoma using dynamic contrast enhanced MRI.Korean J Radiol. 2011 Sep-Oct;12(5):602-10. doi: 10.3348/kjr.2011.12.5.602. Epub 2011 Aug 24. Korean J Radiol. 2011. PMID: 21927562 Free PMC article.
-
RLIP76 regulates HIF-1 activity, VEGF expression and secretion in tumor cells, and secretome transactivation of endothelial cells.FASEB J. 2014 Sep;28(9):4158-68. doi: 10.1096/fj.14-255711. Epub 2014 Jun 13. FASEB J. 2014. PMID: 24928198 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical